 |
| About Bioline | All Journals | Testimonials | Membership | News |
|
||||||
|
||||||
Australasian Biotechnology, Vol. 11, No. 5, 2001, pp. 5-15 NEWS Code Number: au01050
COMMONWEALTH'S $11M FOR 18 BIOLOGICAL R&D PROJECTS The Commonwealth Government provided funding worth more than $11 million under the R&D Start Program for 18 biological projects in the first three months of this year, the Minister for Industry, Science and Resources, Senator Nick Minchin, announced in May. "This latest funding takes the amount awarded to the biological sector for the 2000-1 financial year to almost $37 million for 43 projects," Senator Minchin said. A full list of the projects which received funding from 1 January to 31 March 2001 can be seen at the website http://www.ausindustry.gov.au, together with details of R&D Start and other AusIndustry products. Further information is also available on the AusIndustry HotLine on 13 28 46. SCIENCE GRANTSAustralian Academy of Science Grants are available for international collaboration in scientific research: Scientific Visits:
Postdoctoral Fellowships:
Information and application forms are available from the internet at http://www.science.org.au/internat BIOTECH INDUSTRY UNDER THE MICROSCOPEThe second Australian Biotechnology Industry Report, an in-depth analysis of growth and change affecting one of our country's most rapidly burgeoning industries, was launched in San Diego, California, at the US BIO 2001 conference. Ernst & Young and Freehills prepared the report, following on from the first in 1999, in conjunction with the Department of Industry, Science and Resources, through its Biotechnology Australia division. Its theme of Growth and Global Outreach is exemplified by the extraordinary growth and internationalisation of the industry. It includes forewords from Senator Nick Minchin, Chairman of the Biotechnology Ministerial Council and Minister for Industry, Science and Resources; and Dr John Stocker, AO, on behalf of the industry. The Australian Biotechnology Industry Report focuses on companies in Australia actively involved in the commercialisation of biotechnology, and finds that growing numbers of companies are taking their products and services into global markets. There are now about 60 biotechnology companies listed on the Australian Stock Exchange, with the total number of core biotech companies estimated to be 190, plus a further 460 biotechnology-related companies. Topics covered in the report include significant events in the biotechnology industry, the state of the industry, regulatory matters, and the performance of Australian listed biotechnology companies. The scope of this second report was expanded from the first one to include medical device companies and companies with substantial biotechnology operations. Ernst & Young taxation partner, Keith Hardy, said the value of the report comes from this industry performance analysis. "By comparing Australia's biotechnology performance with that of other countries, we can develop our strengths and position ourselves in the global marketplace," Mr Hardy said. The report finds that the core Australian biotech companies employ more than 5,700 staff, with at least 15 companies opening or expanding in the US or Europe. The industry as a whole raised $900 million in public offerings since 1999, and the core biotech companies generated revenue of nearly $1 billion in the last 12 months. This reflects the rapid and substantial growth of the industry over the last 18 months. According to James Cherry, partner with the biotechnology group at Freehills, the second Australian Biotechnology Report will also serve to promote the Australian industry internationally. CLONAID MAY SUEClonaid may sue the American Authorities for putting an illegal freeze on the human cloning process. Brigitte Boisselier, director of Clonaid, the first laboratory trying to clone a human being, may sue the American authorities for putting an illegal freeze on the process. Since the public announcement by the FDA of the location and inspection of the laboratory, and a letter that it is claimed that Brigitte Boisselier was forced to sign, in which she committed not to undertake human cloning research until she is able to show before a Federal Court that the FDA has no legal jurisdiction on this issue, many American legal experts have provided their support to Clonaid saying that, legally speaking, the FDA has no authority on cloning because it does not involve food nor drugs. Together with many prominent law professors from American universities, they assert that if this case was taken to a Federal Court, the FDA would lose the battle without a doubt. These same experts claim that even if a law forbidding cloning was passed by the US Congress, as was the case for IVF 22 years ago, the Supreme Court of the United States would reverse it and make human cloning a legal technology because the American Constitution guarantees families the right to use any reproduction method they choose without limitations. PREMIER LAUNCHES BIOSCIENCE RESEARCH FACILITIESThe official opening of the $32 million Bioscience Building on 26 July by Victorian Premier, Steve Bracks, represents RMIT University's commitment to strengthening research, development and teaching of biotechnology and medical sciences in Victoria. The purpose-built Bioscience Building at Bundoora in Melbourne's north-west brings together up-to-date facilities, resources and expertise with opportunities for interchange and collaboration between students, staff and industry. The new building is a major step by RMIT University to help position Victoria as a leader in life sciences, the University Chancellor, Don Mercer said. "RMIT University is deeply committed to contributing to the development of the State of Victoria as a leader in biotechnology and medical science, environmental and plant science and diagnostic and therapeutic technologies. The launch of this state-of-the-art building is one part of moving towards that goal," Mr Mercer said. RMIT University's initiative in establishing the new Bioscience Building has been commended by industry. "This facility will enable an integrated approach to R&D for industry, providing a quality research environment with the capacity to scale up new products for trials. It allows the direct translation of technology from the laboratory "bench" through prototype development to the production of batches suitable for registration trials in Australia and overseas," Co-founder and director of Bioproperties Australia Pty Ltd, James Judd said. The Bioscience Building includes a high-tech laboratory complex for teaching and research, boasting the latest advances in information technology. The building has molecular biology, microbiology, haematology, pharmacology, toxicology, ecotoxicology and plant sciences. There are also high-tech core facilities for cell culture, digital imaging, bacterial fermentation, therapeutic drug screening and aquaculture. It is also home to Australia's only virology laboratory accredited by the National Association for Testing Authorities and the Royal Australasian College of Pathologists for the clinical evaluation of influenza vaccines. Diverse research already under way at the new facility includes finding new treatments for diseases such as Alzheimer's, Parkinson's, diabetes and cardiovascular disease, and developing new veterinary vaccines and pest-resistant crops. The new building is part of RMIT University's Faculty of Life Sciences that teaches programs in the areas of biotechnology; environmental and plant science; medical science; diagnostic and therapeutic technologies; nursing, midwifery and health care; physical education and human performance; and complementary medicine. $1.2 MILLION FOR INNOVATION AND SCIENCE AWARENESSThe Minister for Industry, Science and Resources, Senator Nick Minchin, announced on 13 July the first $1.2 million funding round under the new National Innovation Awareness Strategy for projects to raise awareness of the importance of innovation and science. The National Innovation Awareness Strategy recognises the importance of nurturing the next generation of scientists, technologists and entrepreneurs and developing a national culture of innovation. The closing date for applications is Thursday, 30 August. It is expected that successful projects will be announced in October 2001. NEW ZEALAND COMMISSION COMPLETES ITS TASKThe New Zealand Royal Commission on Genetic Modification concluded its inquiry on 27 July with the handing of its Report to the Governor-General, Dame Silvia Cartwright, at Government House. The four-volume Report is the outcome of the Commission's 14-month inquiry. The Commission was set up to report to Government on the options available to New Zealand to deal with genetic modification, and to advise on appropriate changes to the relevant regulatory and policy arrangements. Established on 8 May 2000, the Commission consulted extensively with the New Zealand public on a national basis. Its consultation processes involved scoping meetings and hui, 15 public meetings, 11 hui, 29 workshops, one youth forum and 13 weeks of hearings from 107 interested persons. The Commission also received more than 10,000 public submissions and conducted a public opinion survey of 1153 New Zealanders. The Commission's reporting date was extended from 1 June 2001 to 27 July 2001 to allow it time to consider all the evidence. Cabinet allocated a provisional budget of $4.8 million to the Commission on 17 April 2000. This was extended to $6.2 million on 7 August 2000. The Report is available on the Commission website: http://www.gmcommission.govt.nz
NEW ZEALAND GOVERNMENT RISKS INFLAMING THE GM DEBATEThe decision by the NZ Government to give the Green Party privileged access to the Report of the Royal Commission on Genetic Modification risks inflaming the post-release debate, the Chairman of the Life Sciences Network, Dr William Rolleston, said recently. "We have confirmed the Government intends to give a copy of the Report to the Green Party immediately after the Cabinet meeting; before journalists get access, before all the other interested parties at the hearings. This makes it look as though the Government has decided it doesn't want a balanced debate now the Royal Commission has done its job." "Many of the member organisations of the Life Sciences Network have written to the Prime Minister expressing their dismay." From: Francis Wevers, Executive Director, Biotenz/NZ Life Sciences Network (Inc) Email fwevers@biotenz.org.nz Websites http://www.biotenz.org.nz or http://www.lifesciencenz.com MINCHIN LAUNCHES BIOTECHNOLOGY RESOURCEA new online biotechnology education resource will help young Australians understand the important science of biotechnology and issues such as genetically modified foods and cloning. Launching the resource, Biotechnology Online, at the Australian Science Teachers" Association President's Reception on 11 July, Senator Nick Minchin said the growing community debate about biotechnology had been fraught with misunderstanding and misinformation. "This resource will help teachers impart a basic understanding of biotechnology and gene technology to students. It will help them contribute to the debates on the ethical, legal and social questions thrown up by this rapidly advancing field," he said. "The regulation of gene technology and the safety and labelling of genetically modified foods, are just two areas where we need to reliably inform people of the facts." Biotechnology Online, has been developed over ten months by the multi-Departmental Commonwealth Government agency, Biotechnology Australia, working with the Australian Science Teachers Association and curriculum development agencies from every state and territory. Biotechnology Online can be viewed at http://www.biotechnology.gov.au/education/education.asp Or for those interested in obtaining a CD copy of Biotechnology Online, contact the Gene Technology Information Service on 1800 631 276I. LAW ON REGULATING HUMAN CLONING TECHNIQUES ESTABLISHED IN JAPANIn November 2000, the Law Concerning Regulation of Human Cloning Techniques, which strictly forbids the creation of human clones, because of the possibility that it could have a serious effect on such things as the preservation of human dignity, was established in Japan. (Promulgated on 6 December 2000).
Further information: http://www.mext.go.jp/a-menu/shinkou/seimei/eclone.pdf Reproduced from Japan Bioindustry Letters, Vol 17 No 3/4, March 2001 MAJOR BIOSCIENCE INITIATIVE FOR SOUTH AUSTRALIAThe high-tech bioscience industry is set to become a leading driver of the State's economy following the launch of a major initiative by the South Australian Government. Deputy Premier Rob Kerin recently announced AUD$12.5 million in South Australian Government funding and the launch of a strategic plan, Bright is the Future, to guide the long-term development of the bioscience industry in South Australia. The AUD$12.5 million in funding will be made available over the next four years and will be used to provide commercialisation and pre-seed support initiatives and the creation of a bioscience business incubator. Mr Kerin said the funding was part of the South Australian Government's long-term commitment to funding the bioscience industry and turning ideas into income for the benefit of both the State and the increasing number of bioscience-focused companies operating in South Australia. "The foundations are already well in place for South Australia to become a leading national bioscience "hub". More than AUD$290 million has been invested in the State's bioscience research and development (R&D) infrastructure in recent years," he said. "The growing importance of this sector to the State is already evident in the fact that some AUD$200 million is spent annually on lifesciences R&D in South Australia. It is predicted that this new initiative could, over the next 10 years, result in the establishment of 50 new bioscience companies, the creation of 2400 jobs and investment of at least AUD$600 million. Already in recent years, the floats of local bioscience companies GroPep, Bionomics and BresaGen have resulted in AUD$57 million being injected into the State's biotechnology sector. Local start-up bioscience companies eligible to apply for the Commonwealth Biotechnology Innovation Fund will be able to apply for part matching funds through this latest SA initiative. Some of the funds will be used by Bio Innovation SA, the Government agency charged with the development of the State's bioscience sector, for ongoing industry support activities. This follows on from the AUD$4 million already invested in Bio Innovation SA. The Bright is the Future strategic plan, developed by Bio Innovation SA, aims to encourage major bioscience activity, attract bioscience companies and secure long-term economic benefits for South Australia. The strategic plan encourages a collaborative approach to research and development, particularly in areas such as biomedical and agricultural research, in which South Australia has world-class strengths. The strategy also aims to enhance the entrepreneurial culture within universities and research organisations, to assist bioscience start-ups, support relationships between research and industry for greater commercial outputs and promote the State's bioscience capabilities nationally and internationally. POWERFUL ALLIANCE FORMED IN BIOINFORMATICS AND GENOMICSThe sequencing of the human genome and the worldwide shortage of trained bioinformaticists to help interpret the genome has precipitated the formation of an international alliance to present accredited online courses in bioinformatics. Stanford University, USA, University of Uppsala, Sweden, the Karolinska Institute, Sweden, the National University of Singapore, the University of Sydney and the University of Western Cape, South Africa have formed a global alliance that is to provide a global, bioinformatics unified learning environment (GLOBULE) made up of modular courses in genomics and bioinformatics. The group consists of members from universities, cities or countries starting with the letter 's" and so has adopted computer terminology to form the S* consortium (http://www.s-star.org). Short-term, the alliance will make a jointly provided globally accessible online course for training in bioinformatics available. Students will have access to world experts who have generated the highest quality of online courseware available. The courses will be aimed at 3rd year undergraduate/ masters students and graduate students in the discipline of bioinformatics, structural biology and medical informatics. Students will have the unique opportunity to interact with teachers and students of many different nationalities working across time zones and continents. Further information: Anthony Weiss, University of Sydney, NSW, Tel: (02) 9351 3464, Email: director@biotech.usyd.edu.au INCREASED ACCEPTANCE OF GENETICALLY MODIFIED FOODSDespite a common perception that genetically modified (GM) foods are currently not beneficial for society, more people are willing to eat GM foods than would not eat them. This is one of the findings related to GM foods from a survey undertaken for the Commonwealth Government Agency, Biotechnology Australia, and released recently. Speaking at the Australian Institute for Food Science and Technology Conference in Adelaide, Craig Cormick, Manager of Public Awareness at Biotechnology Australia, said that the study demonstrated several changes in attitude since a comparable study was undertaken in 1999. "These benchmark studies are very important, because they show trends in attitude change," Mr Cormick said. The survey found that 32% of people were either extremely concerned or very concerned about GM foods, with only 48% somewhat concerned, yet 49% would eat GM foods. "We have seen this figure, for those in Australia who would eat GM foods, rise from 25% in 1999 to 32% in 2000 - and now to almost 50%," Mr Cormick said. The survey also found that there was a decrease of 9% amongst those who thought GM foods were useful to society, and an increase of 6% of those who thought GM foods were a risky application for society. "Consumers appear to be becoming more discerning about the actual benefits of GM foods," Mr Cormick said. "For instance, in 1999, 51% of people said they would eat GM foods that had been engineered to taste better - but in 2001, this had dropped to 43%. By comparison, 60% of people said that they would eat GM foods if they had been modified to be healthier." "Trends indicate an increased acceptance of GM foods if they are demonstrated to be useful or provide direct consumer benefits, such as the cotton plants genetically modified to produce healthier cooking oils and margarines, developed recently by the CSIRO; and also if GM foods are labelled - which will happen in Australia in December this year," he said. Mr Cormick said that, while understanding of GM food was increasing, there were still many myths widely accepted, such as 64% of people believing that there were fresh fruit and vegetables that had been genetically modified available in supermarkets - when in fact there are none. "The only GM foods currently available in Australia are soy, canola oil, processed corn, potato starch, sugar beet products and cotton seed oil - the cotton seed oil being the only food available from a GM crop grown in Australia. He also said that they survey showed increased awareness of Government regulatory agencies, with the Australia New Zealand Food Authority's recognition rising from 36% to 39% and trust in it increasing from 67% to 73%. TRANS-TASMAN GRAIN ALLIANCE ANNOUNCEDAusgrainz, an alliance between Australia's CSIRO and New Zealand's Crop and Food Research (C&FR) should lead to increased competitiveness in the global grains markets which came into effect on 2 August 2001. The trans-Tasman agreement between the public research organisations will expand the two countries" plant breeding efforts by widening access to international germ plasm and building the scientific research base. Australia's wheat industry alone is worth around $4.5 billion, with around $3.8 billion of that coming from exports. New Zealand's grains industry is valued at around $500 million, with considerable scope for developing niche market products. 'science and technology have been one of the key drivers for the success and growth of the Australian grains industry," says CSIRO Plant Industry Chief, Dr Jim Peacock. "And science and technology will continue to increase the value of that market and Australia's other grains markets by developing more premium cultivars with additional traits like better disease resistance, performance in a greater range of conditions and quality characteristics for end products." MALAYSIA UNVEILS PLAN FOR BIOVALLEYMalaysia's National Biotechnology Directorate (NBD) has proposed the government to set up a BioValley in the country to house the biotechnology industry. The proposal was made by the Managing Director of NBD, Dr Abdul Latiff Ibrahim, during a seminar recently. He said that BioValley would comprise three biotechnology institutes and a business development directorate. The institutes would be dedicated to studies in genomics, molecular biology, agricultural biotechnology, nutraceuticals and pharmaceuticals. The business development directorate would identify innovations for commercialisation. About 50 home-grown companies would also be based there. The cabinet has agreed in principle to the proposed plans for the BioValley. The BioValley, which will be located within the Multimedia Super Corridor, will be developed under the Eighth Malaysia Plan (2001 - 2005). Dr Latiff said that the BioValley is projected to grow from a RM2 billion (US$526 million) industry to RM5 billion (US$1.32 billion) industry within seven years of establishment. The Malaysian government is formulating a National Biotechnology Policy for the development of this sector. Malaysia's Deputy Prime Minister, Datuk Seri Abdullah Ahmad Badawi, said that the Policy was necessary for a holistic approach to growth of the industry. He added that the government has allocated RM1100 million (US$26.3 million) for research in agro-biotechnology, medicine, environmental and energy management. Reproduced from Asia Pacific Biotech News 5 (11) 2001. COMMUNITY HAS NEW CONCERNS ABOUT GENE TECHNOLOGYEthics, cloning and health-related applications head the list of community concerns about biotechnology and gene technology, according to the largest and most comprehensive tracking survey of public attitudes in this field. The survey was conducted by the research firm, Millward Brown, for the Commonwealth Government agency, Biotechnology Australia, in April and May this year. It involved both quantitative and qualitative research with 1200 people from the general public being surveyed. Manager of Public Awareness at Biotechnology Australia, Craig Cormick, said that, while much of the public debate and media coverage is focussed on genetically modified (GM) crops and foods, the research demonstrates that individuals" concerns are starting to move towards more complex societal issues. The research is an update of a study conducted in late 1999 and provides data on how community attitudes have changed towards different issues in that time. Major changes include:
There was also an increase in the percentage of the population who believed genetic engineering would improve our lives over the next 20 years (from 42% to 51%). There was, however, a decrease in acceptance of using animal genes in plants (51% down to 31%) or of modifying human genetic material with animal genes (51% down to 44%). There was an increase in the perceived risk of using human genes in animals to grow organs for transplantation (66% to 75%). "The study also found that, while 80% of the community had some level of concern about gene technology, these concerns rated much lower than environmental concerns such as pollution or greenhouse gases," Mr Cormick said. While the highest level of awareness for any application was cloning (98%), it also had a very high negative rating, with 58% stating they believed it would make things worse in the next 20 years. However it ranked as a lesser concern than pollution or greenhouse gasses. "Overall, the survey indicated that the community did not feel well informed on many biotechnology issues," Mr Cormick said. " People felt they should know more about them and that some misconceptions prevailed. For example, some respondents incorrectly believed that if an animal ate GM feed, it would become genetically modified. They also incorrectly believed that there were GM fresh fruits and vegetables available in supermarkets." "The research also showed that individuals make complex evaluations of different applications of biotechnology based on why the modification was undertaken, who would benefit from it and what the risks versus benefits of each application were. "It is clear from the research that ethical concerns were very influential in attitude formation, often being based upon whether the modification was developed with the aim of benefiting society. Applications that were perceived to have only cosmetic benefits, such as improving the tastes of food by genetic modification, were rated more negatively," Mr Cormick said. Trust in Government agencies both as a source of factual information and as regulators, rose during the period. The CSIRO was rated as an agency that the public had the most confidence in - with 85% saying it was a credible source of information (up from 80% in 1999), and Biotechnology Australia was rated as credible by 58% of respondents. Trust in the Australia New Zealand Food Authority rose from 67% to 73% and trust in the Office of Gene Technology Regulator rose from 71% to 73%. The full survey report is available from the What's New page of the Biotechnology Australia website at: http://www.biotechnology.gov.au/Whats_New/index.asp EXPERT PANEL FOR BIOTECHNOLOGY CENTRESenator Minchin. Minister for Industry, Science and Resources, and Dr Kemp, Minister for Education Training and Youth Affairs, have announced the expert panel for the Biotechnology Centre of Excellence. This initiative is part of the Backing Australia's Ability statement, and the need for such a move was identified in the National Biotechnology Strategy, released in July 2000. Chair of the Panel is Dr Peter Jonson, Chairman of the Melbourne Institute and consultant with Ernst & Young. The Vice-Chair is Professor Merilyn Sleigh, Dean of the Faculty of Life Sciences at the University of New South Wales. Members of the Panel are:
For more information, visit http://www.innovation.gov.au or email ba@isr.gov.au GM TRIAL SITES LISTED BY THE OGTRThe Office of the Gene Technology Regulator (OGTR) has made public the details of 518 of 629 GM crop sites currently in operation across Australia. This amounts to approximately 83% of all trial sites being listed. The details, which include exact satellite coordinates of trial sites, are available on the OGTR website http://www.ogtr.gov.au The remaining sites are presently being assessed under commercial-in-confidence provisions that were included in the Gene Technology Act 2000. The OGTR has 90 days to assess these applications. Any applications the fail to meet the strict criteria for commercial-in-confidence will become publicly listed on the website. Australia's largest GM crop tester, Aventis CropScience, agreed to list all of its 283 trial sites, as have CSIRO. Aventis general manager, Dr Max Cowie, expressed disappointment that the details of past trial sites were required to be disclosed alongside those currently under trial. Monsanto Australia applied for secrecy for 80 of its trial sites, citing farmer and property protection as its main concerns. The University of Queensland also submitted commercial-in-confidence applications for its trials of GM sugar cane, pineapple and prawns, citing similar fear of damage by trespassers as their main concern. Indeed, a Queensland trial of GM pineapples was destroyed last year by anti-GM protesters. The disclosure of trial sites has been seen as essential in keeping the public debate regarding gene technology open and transparent. However, some critics have expressed concerns that the format is inaccessible to the general public, as sites are not listed by location, and only cryptic GPS coordinates are given. The OGTR insists that maps and better Internet navigation features will be incorporated into updates of the trial sites database. Source: Gene Technology Information Service CARR UNVEILS NSW BIOTECH STRATEGYThe New South Wales Premier, Bob Carr, unveiled the NSW biotechnology strategy at the CHIF/ABA conference in Sydney, with funding of $68 million over five years to support its initiatives. The Strategy, called BioFirst, is divided into four programs: BioPLATFORM ($47.5 million), BioBUSINESS ($13 million), BioETHICS (4.35 million) and BioUNIT ($2.95). As one of the first actions, the BioUNIT will be set up with the Cabinet Office to oversee implementation of the strategy. BioPLATFORM will focus on building biotechnology infrastructure, staff and training. Initiatives include:
The Treasurer and Minister for State Development, Michael Egan, has subsequently announced the formation of a $9.65 million fund to support Major National Research Facilities selected under the Commonwealth's program. Of this money, $3.15 million is new funds, and $6.5 million is part of the $68 million. GLOBAL EXPANSION FOR STEM CELL SCIENCESStem Cell Sciences Ltd, a Melbourne based biotechnology company, has announced the creation of a wholly owned UK subsidiary Stem Cell Sciences (UK) Ltd. The new Company has established offices and laboratories within the Centre for Genome Research (CGR), the University of Edinburgh, Scotland. "Many believe that stem-cell biotechnology will become the new "holy grail" of medical science. The competition however is hotting up fast, requiring a global perspective and global investment strategy for our Melbourne-based company," said Dr Peter Mountford, Chief Executive Officer of SCS. "Our first patent, which provides SCS with the exclusive right to use the only known technology capable of purifying any stem cell, has now been granted in the USA and Europe. Broad patent protection in these key territories and validation of the technology in our first gene and drug discovery alliance with Aventis Pharma this year, has signalled the green light for rapid expansion of the company" added Dr Mountford. SCS has established a portfolio of patented technologies to harness the great potential of Embryonic Stem (ES) cells in the development of new human therapies. ES cells are the cells from which all cell types in the body are derived. ES cells can be grown indefinitely in the laboratory and therefore provide an unlimited source of potentially any cell type for gene and drug discovery and the development of cell-based therapies. Dr Mountford said, "The establishment of a UK facility allows SCS to better relate and respond to commercial opportunities within Europe as a whole. It will also permit SCS to directly interact with a wealth of excellent scientists at the University of Edinburgh and represents a significant development in the growth of SCS." CROWN SCIENTIFIC BECOMES EXCLUSIVE AGENT FOR CAMSPECCrown Scientific has announced that it has been appointed the exclusive laboratory distributor for Camspec's entire range of UV spectrophotomers, a microprocessor-controlled range with easy connection to PC's and a computer-controlled double beam with Windows software. A new addition is the M400 fibre optic spectrophotometer that does not require cells. Email: marketing@crownsci.com.au
Copyright 2001 - AusBiotech | ||||||||||||||||||||||||||||||||||||||
| |||||||||
